Key Points

- Zacks Rank system focuses on earnings estimates and revisions for stock picks
- Identifying low-priced stocks with high growth potential using P/B ratio
- Highlighting 5 low Price-to-Book Value stocks including USNA, CVS, PFE, STNE, and PSFE
- Pfizer's share price decline over various time frames
- Considerations for value investors looking to buy Pfizer (PFE) stock

Zacks, a renowned platform for stock analysis, places significant emphasis on their proven Zacks Rank system, which prioritizes earnings estimates and revisions to pinpoint top-performing stocks. However, they also keep a keen eye on prevailing value, growth, and momentum trends to identify robust investment opportunities. In a recent analysis, Zacks highlighted 5 low Price-to-Book Value stocks, including USNA, CVS, PFE, STNE, and PSFE, showcasing their potential for growth despite being priced at a lower value.

One key metric used in determining undervalued stocks with substantial growth prospects is the Price-to-Book (P/B) ratio. This ratio helps investors identify stocks trading at a discount compared to their book value, indicating the potential for significant price appreciation in the future. Among the list of stocks with favorable P/B ratios, Pfizer (PFE) stands out as a potential value investment opportunity.

Despite its strong position in the market, Pfizer (PFE) has seen a decline in its share price over various time frames. Whether considering year-to-date performance, the last 12 months, or even the last five years, Pfizer's stock price has shown a downward trend. This trend may present an attractive entry point for value investors looking to capitalize on the long-term growth potential of the company.

For value investors seeking to add beaten-down stocks with solid dividend yields to their portfolio, Pfizer (PFE) could present a compelling option. With a dividend yield of 7%, Pfizer offers an attractive income opportunity for investors looking to generate passive income while waiting for the stock price to rebound. By strategically timing their entry into the market, value investors can potentially benefit from both capital appreciation and dividend payouts in the future.

Analyzing Pfizer (PFE) stock through the lens of a value investor reveals intriguing possibilities for long-term growth and income generation. Despite its recent share price decline, Pfizer's solid fundamentals and attractive dividend yield make it a stock worth considering for value-oriented portfolios. By incorporating a blend of fundamental analysis and value investing principles, investors can make informed decisions about whether Pfizer (PFE) aligns with their investment objectives and risk tolerance.

About PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

For more information:

Up/Down Rally

Price Distribution

Analyst Recommendations

Earning Price Impact Analysis

Seasonality